These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29641325)

  • 21. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
    Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
    AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dendritic cell based vaccines for HIV infection: the way ahead.
    García F; Plana M; Climent N; León A; Gatell JM; Gallart T
    Hum Vaccin Immunother; 2013 Nov; 9(11):2445-52. PubMed ID: 23912672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication.
    García F; Climent N; Guardo AC; Gil C; León A; Autran B; Lifson JD; Martínez-Picado J; Dalmau J; Clotet B; Gatell JM; Plana M; Gallart T;
    Sci Transl Med; 2013 Jan; 5(166):166ra2. PubMed ID: 23283367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. May immunization strategies that target dendritic cells really offer advantages for HIV-1?
    Costa P; Beltrame A; De Maria A
    AIDS; 2006 Jun; 20(9):1351-2. PubMed ID: 16816576
    [No Abstract]   [Full Text] [Related]  

  • 25. Treating HIV-1 infection with dendritic cells.
    Connolly NC; Colleton BA; Rinaldo CR
    Curr Opin Mol Ther; 2007 Aug; 9(4):353-63. PubMed ID: 17694448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evasion of adaptive immunity by HIV through the action of host APOBEC3G/F enzymes.
    Grant M; Larijani M
    AIDS Res Ther; 2017 Sep; 14(1):44. PubMed ID: 28893290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection.
    Horton H; Havenar-Daughton C; Lee D; Moore E; Cao J; McNevin J; Andrus T; Zhu H; Rubin A; Zhu T; Celum C; McElrath MJ
    J Virol; 2006 Oct; 80(19):9779-88. PubMed ID: 16973582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Future considerations for dendritic cell immunotherapy against chronic viral infections.
    Atanley E; van Drunen Littel-van den Hurk S
    Expert Rev Clin Immunol; 2014 Jun; 10(6):801-13. PubMed ID: 24734867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.
    Ide F; Nakamura T; Tomizawa M; Kawana-Tachikawa A; Odawara T; Hosoya N; Iwamoto A
    J Med Virol; 2006 Jun; 78(6):711-8. PubMed ID: 16628588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Negative modulation of suppressive HIV-specific regulatory T cells by IL-2 adjuvanted therapeutic vaccine.
    Brezar V; Hani L; Surenaud M; Hubert A; Lacabaratz C; Lelièvre JD; Levy Y; Seddiki N
    PLoS Pathog; 2017 Jul; 13(7):e1006489. PubMed ID: 28708863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation.
    Vacas-Córdoba E; Climent N; De La Mata FJ; Plana M; Gómez R; Pion M; García F; Muñoz-Fernández MÁ
    Nanomedicine (Lond); 2014 Dec; 9(17):2683-702. PubMed ID: 25529571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exome analysis of HIV patients submitted to dendritic cells therapeutic vaccine reveals an association of CNOT1 gene with response to the treatment.
    Moura R; Pontillo A; D'Adamo P; Pirastu N; Campos Coelho A; Crovella S
    J Int AIDS Soc; 2014; 17(1):18938. PubMed ID: 24433985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment.
    van den Ham HJ; Cooper JD; Tomasik J; Bahn S; Aerts JL; Osterhaus ADME; Gruters RA; Andeweg AC;
    PLoS One; 2018; 13(2):e0192278. PubMed ID: 29389978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial.
    Boffito M; Fox J; Bowman C; Fisher M; Orkin C; Wilkins E; Jackson A; Pleguezuelos O; Robinson S; Stoloff GA; Caparrós-Wanderley W
    Vaccine; 2013 Nov; 31(48):5680-6. PubMed ID: 24120550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Towards the development of a therapeutic vaccine for the treatment of HIV-1 infection: are we closer than ever?
    Egan MA
    Expert Rev Vaccines; 2007 Jun; 6(3):289-91. PubMed ID: 17542741
    [No Abstract]   [Full Text] [Related]  

  • 36. Dendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-Analysis.
    Coelho AV; de Moura RR; Kamada AJ; da Silva RC; Guimarães RL; Brandão LA; de Alencar LC; Crovella S
    Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27898045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritic cells as a conduit to improve HIV vaccines.
    Pope M
    Curr Mol Med; 2003 May; 3(3):229-42. PubMed ID: 12699360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV.
    Filaci G; Fenoglio D; Taramasso L; Indiveri F; Di Biagio A
    Front Immunol; 2018; 9():2447. PubMed ID: 30459765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1 evolution in patients undergoing immunotherapy with Tat, Rev, and Nef expressing dendritic cells followed by treatment interruption.
    de Goede AL; van Deutekom HW; Vrancken B; Schutten M; Allard SD; van Baalen CA; Osterhaus AD; Thielemans K; Aerts JL; Keşmir C; Lemey P; Gruters RA
    AIDS; 2013 Nov; 27(17):2679-89. PubMed ID: 24149085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers.
    Kikuchi T; Iwabu Y; Tada T; Kawana-Tachikawa A; Koga M; Hosoya N; Nomura S; Brumme ZL; Jessen H; Pereyra F; Trocha A; Walker BD; Iwamoto A; Tokunaga K; Miura T
    J Virol; 2015 May; 89(9):4992-5001. PubMed ID: 25717111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.